Sanctuary Advisors LLC Acquires 1,649 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Sanctuary Advisors LLC raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,631 shares of the biopharmaceutical company’s stock after purchasing an additional 1,649 shares during the quarter. Sanctuary Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $31,393,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Ellerson Group Inc. ADV boosted its position in Regeneron Pharmaceuticals by 0.5% during the first quarter. Ellerson Group Inc. ADV now owns 8,079 shares of the biopharmaceutical company’s stock worth $6,242,000 after purchasing an additional 44 shares during the period. Sigma Planning Corp raised its position in shares of Regeneron Pharmaceuticals by 159.9% in the first quarter. Sigma Planning Corp now owns 2,012 shares of the biopharmaceutical company’s stock valued at $1,555,000 after purchasing an additional 1,238 shares during the period. Checchi Capital Advisers LLC raised its position in shares of Regeneron Pharmaceuticals by 22.9% in the first quarter. Checchi Capital Advisers LLC now owns 595 shares of the biopharmaceutical company’s stock valued at $460,000 after purchasing an additional 111 shares during the period. Nwam LLC lifted its stake in shares of Regeneron Pharmaceuticals by 11.3% during the 1st quarter. Nwam LLC now owns 1,917 shares of the biopharmaceutical company’s stock worth $1,481,000 after buying an additional 195 shares during the last quarter. Finally, Maryland State Retirement & Pension System lifted its stake in shares of Regeneron Pharmaceuticals by 1.2% during the 1st quarter. Maryland State Retirement & Pension System now owns 5,090 shares of the biopharmaceutical company’s stock worth $3,933,000 after buying an additional 61 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on REGN shares. Morgan Stanley decreased their price target on shares of Regeneron Pharmaceuticals from $788.00 to $730.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 8th. Leerink Partners restated a “market perform” rating and set a $641.00 price objective (down from $792.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, May 18th. TD Cowen raised their price objective on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a research report on Thursday, April 23rd. HSBC reduced their price objective on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a report on Monday, July 6th. Finally, Barclays decreased their target price on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $787.67.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 200 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director directly owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 1.3%

REGN stock opened at $664.45 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. The company’s 50-day simple moving average is $642.36 and its 200 day simple moving average is $719.45. Regeneron Pharmaceuticals, Inc. has a 52 week low of $541.00 and a 52 week high of $821.11. The company has a market capitalization of $70.25 billion, a PE ratio of 16.19, a price-to-earnings-growth ratio of 1.45 and a beta of 0.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. During the same period last year, the firm earned $8.22 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 19.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.16 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.16%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.